Your shopping cart is currently empty

Contezolid (MRX-I) is an orally available oxazolidinone antibiotic with bactericidal activity that can be used to study complications of skin tissue infections and tuberculosis caused by drug-resistant Gram-positive bacteria.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $228 | In Stock | In Stock | |
| 5 mg | $562 | In Stock | In Stock | |
| 10 mg | $828 | In Stock | In Stock | |
| 25 mg | $1,650 | In Stock | In Stock | |
| 50 mg | $2,320 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $619 | In Stock | In Stock |
| Description | Contezolid (MRX-I) is an orally available oxazolidinone antibiotic with bactericidal activity that can be used to study complications of skin tissue infections and tuberculosis caused by drug-resistant Gram-positive bacteria. |
| In vitro | Contezolid activity against MRSA strains (MIC50/90, 0.5/1 mg/liter; highest MIC, 1 mg/liter) was equivalent to that observed against MSSA strains (MIC50/90, 0.5/1 mg/liter; highest MIC, 2 mg/liter). [1] |
| In vivo | The ED50s of Contezolid against S. aureus ATCC 29213, 15, ATCC 33591, Mu50, and 0850 were 7.98, 5.74, 2.36, 2.50, and 3.71 mg/kg. Five different doses (5.0, 10.0, 20.0, 40.0, and 80.0 mg/kg) of Contezolid and the reference compound linezolid were orally administered twice, at 2 h and 6 h after infection, respectively. [2] |
| Synonyms | MRX-I, MRXI, MRX I |
| Molecular Weight | 408.33 |
| Formula | C18H15F3N4O4 |
| Cas No. | 1112968-42-9 |
| Smiles | O=C1N(C[C@H](CNC=2C=CON2)O1)C3=C(F)C(F)=C(C(F)=C3)N4CCC(=O)C=C4 |
| Relative Density. | 1.528 g/cm3 (Predicted) |
| Storage | keep away from direct sunlight,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (244.9 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (9.8 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.